-
November 17: Causal Inference and Causal Estimands From Target Trial Emulations Using Evidence from Real-World Observational Studies and Clinical Trials - In Person at ISPOR Europe 2024
-
The Burden of Time: MS Treatment and Socio-Economic Impact Reduction
-
IRA Part III: Medicare’s Maximum Fair Prices for the First 10 Negotiated Drugs and Anticipated Cost Savings
-
October 16-17: Applying RWD and Novel Data Sources to Advance Patient-Centric Health Equity, Outcomes, and Economic Evaluations- Virtual
-
Evidence Generation for JCAs: How Can AI Boost Efficiency and Maintain Quality?
-
Global Perspective on Inequality Aversion: Methods and Learnings
-
Patient Involvement in Value and Health Technology Assessment (V/HTA)
-
Conducting Research and Survey Studies in Hard-to-Reach Populations
-
Can GenAI for Literature Reviews Ever Be Trusted? A Pragmatic Approach That’s Ethically Designed and Purpose-built for HEOR Professionals
-
October 2-3: Introduction to Best Practices for Country Adaptations of Economic Models- Virtual
-
September 25-26: Understanding Survival Modeling with Application to HTA- Virtual
-
Transferability of Data and Methods to Central and Eastern Europe
-
September 18-19: Introduction to Clinical Outcome Assessments (COAs): Selecting, Modifying, or Developing Fit-for-Purpose Measures- Virtual
-
September 4-5: Practical Applications of Large Language Models for Real World Evidence Generation and HEOR- Virtual
-
Moving Toward Universal Health Coverage in Africa: The Role of HTA
-
July 24-25: Automated Health Economic Analysis using R Shiny- Virtual
-
IRA Part II: Next 15 For Medicare Drug Price Negotiations in 2025
-
July 10-11: Causal Machine Learning for Health Economics and Outcomes Research- Virtual
-
The Role of RWE for Devices and Diagnostic Market Access in Europe
-
June 26-27: Leveraging Clinical Outcome Assessment (COA) Data to Maximize the Value of New Treatments Beyond Labeling- Virtual